The consolidated results of Shire and Baxalta exceeded both the Street and our expectations. Total revenue staged a growth of 56% to $2.4bn, o/w 19% ($1.8bn) came from Shire’s standalone portfolio and the remaining from Baxalta’s one month contribution (c.$559m). Growth was seen across Vyvanse (+22%), Cinryze (+25%), Firazyr (+31%), Adderall XR (+18%), Lialda (+23%), Pentasa (+10%), Gattex/Revestive (+19%), and Natpara. Royalties and other revenue also improved 30% yoy, mainly ben
17 Aug 2016
Strong results, accretion/synergy targets upped
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong results, accretion/synergy targets upped
Shires Income PLC GBP (SHRS:LON) | 222 -1.1 (-0.2%) | Mkt Cap: 92.0m
- Published:
17 Aug 2016 -
Author:
Kamla Singh -
Pages:
3
The consolidated results of Shire and Baxalta exceeded both the Street and our expectations. Total revenue staged a growth of 56% to $2.4bn, o/w 19% ($1.8bn) came from Shire’s standalone portfolio and the remaining from Baxalta’s one month contribution (c.$559m). Growth was seen across Vyvanse (+22%), Cinryze (+25%), Firazyr (+31%), Adderall XR (+18%), Lialda (+23%), Pentasa (+10%), Gattex/Revestive (+19%), and Natpara. Royalties and other revenue also improved 30% yoy, mainly ben